Enzalutamide, a non-steroidal select antagonist of the androgen receptor, has been implicated in the reduction of TMPRSS2 levels in lung cells [54] and its role in COVID-19 treatment has been tested in a double-blinded, randomized phase II clinical trial [55]. Here, TMPRSS2 is linked to COVID-19.